Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
South Korea Prosecutor Alleges Former First Lady Kim Keon Hee Abused Power for Bribes 
Singapore GDP Growth Surges in 2025 but Outlook Remains Cautious Amid Global Trade Risks 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Asia Manufacturing PMI Rebounds as Exports and Tech Demand Drive Growth into 2026 
Trump Delays Tariff Increases on Furniture and Cabinets for One More Year 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
U.S. Stock Futures Slip as Year-End Trading Turns Cautious 
Forex Markets Hold Steady as Traders Await Fed Minutes Amid Thin Year-End Volumes 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
U.S. Judge Blocks Deportation of British Anti-Disinformation Campaigner Imran Ahmed Amid Free Speech Dispute 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Federal Reserve Begins Treasury Bill Purchases to Stabilize Reserves and Money Markets 
China Imposes 55% Tariff on Beef Imports Above Quota to Protect Domestic Industry 
South Korea Exports Hit Record High as Global Trade Momentum Builds 
DOJ Releases New Epstein Files Detailing Alleged Trump Flights on Private Jet 
Democratic Attorneys General Sue Trump Administration Over Proposed Limits on Gender-Affirming Care for Youth 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
